Oncolytics Logo
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

News Releases

  • News Releases
Latest News Release
Jun 12, 2015

Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders

Jun 9, 2015

Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of Shareholders

Jun 8, 2015

Oncolytics Biotech® Inc. Provides Update at AGM on Planned Registration Program for REOLYSIN®

Jun 5, 2015

Oncolytics Biotech® Inc. Announces Details of 2015 Annual Meeting of Shareholders

Jun 2, 2015

Media Advisory – Oncolytics Biotech® Inc. to Participate in the LD Micro Invitational Conference

May 19, 2015

Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors

May 7, 2015

Oncolytics Biotech® Inc. Announces 2015 First Quarter Results

May 6, 2015

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Year
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • News
Dec 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Dec 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles
Aug 9, 2016

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

@Oncolytics Jun 28, 2022

The GOBLET study abstract at #WCGIC2022 shows the first three pancreatic cancer patients all had partial responses… https://t.co/J00D2hCaHD

@Oncolytics Jun 17, 2022

Voting results from the Annual General Meeting of Shareholders are available in the PR below, we're also excited to… https://t.co/3OtCS3smJw

Follow us on Twitter
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

Sign up to receive email updates

Sign Up
Linkedin Icon
  • Privacy | Legal Notice
Copyright © Oncolytics Biotech® Inc. 2022 All rights reserved

Site by
Site by Pace Creative Alberta Site by Pace Creative Alberta